调节性T细胞治疗移植物抗宿主病的治疗应用
本文综述调节性T细胞(Treg细胞)的生物学特性及其在移植物抗宿主病(GvHD)中的作用,重点讨论过继转移Treg细胞和治疗性调节其活性在临床前模型和临床环境中预防和治疗GvHD的应用,并探讨临床应用的主要障碍。
要点
- Treg细胞是CD4+ T细胞谱系,在抑制自身和外来抗原免疫反应及炎症中起关键作用。
- 过继转移Treg细胞或调节其活性可用于预防和治疗GvHD。
- Treg细胞疗法在GvHD临床实践中仍存在主要障碍。
核心结论
- Treg细胞过继转移和活性调节是预防和治疗GvHD的有前景策略,但临床转化仍面临障碍。
研究设计与样本
- 综述,描述Treg细胞基本生物学特性及其在GvHD中的作用,聚焦过继转移和活性调节在临床前模型和临床环境中的应用。
主要发现
- Treg细胞抑制自身和外来抗原免疫反应及相关炎症。
- 抑制或去除Treg细胞可增强抗恶性肿瘤免疫。
- 增强Treg细胞活性可用于治疗炎症或自身免疫病及移植相关同种免疫冲突。
- GvHD是造血干细胞移植(HSCT)后发病和死亡的主要原因。
临床怎么用
- 过继转移Treg细胞或治疗性调节其活性可用于GvHD的预防和治疗。
局限性
- Treg细胞疗法应用于GvHD临床实践存在主要障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regulatory T cells (Treg cells) represent a CD4+ T-cell lineage that plays a critical role in restraining immune responses to self and foreign antigens and associated inflammation. Due to the suppressive function of Treg cells, inhibition or ablation of these cells can be used to boost the immunity against malignant cells. On the other hand, augmenting the activity of Treg cells can be employed for the treatment of inflammatory or autoimmune diseases and allogeneic conflicts associated with transplantation. Graft-versus-host disease (GvHD) is a leading cause of morbidity and mortality after haematopoietic stem cell transplantation (HSCT). In this review, we describe basic biological properties of Treg cells and their role in GvHD. We focus on the application of adoptive transfer of Treg cells and the therapeutic modulation of their activity for the prevention and treatment of GvHD in pre-clinical models and in clinical settings. We also discuss the main obstacles to applying Treg cell-based therapies for GvHD in clinical practice.
引用
- Elias S, Rudensky AY. Therapeutic use of regulatory T cells for graft-versus-host disease. Br J Haematol. 2019. PMID: 31418827. doi:10.1111/bjh.16157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。